Translational Development Acquisition (TDACW) Change in Accured Expenses (2024 - 2026)

Translational Development Acquisition (TDACW) has reported Change in Accured Expenses for 3 consecutive years, with $260465.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Accured Expenses rose 516.36% year-over-year to $260465.0; the trailing twelve-month figure through Jun 2026 stood at $246868.0 (up 158.9% YoY), and the FY2025 full-year result was $29008.0, up 106.45% from the prior year.
• Change in Accured Expenses advanced to $260465.0 in Q2 2026 per TDACW's latest filing, from -$12988.0 in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $260465.0 in Q2 2026 and bottomed at -$469542.0 in Q4 2024.
• Historically, Change in Accured Expenses has averaged -$21532.1 across 3 years, with a median of -$304.5 in 2025.
• The widest YoY moves for Change in Accured Expenses: up 516.36% in 2026, down 114.09% in 2026.
• Over 3 years, Change in Accured Expenses stood at -$469542.0 in 2024, then soared by 98.13% to -$8772.0 in 2025, then jumped by 3069.28% to $260465.0 in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $260465.0, -$12988.0, and -$8772.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.